

## Special Issue

# COVID-19 Vaccine-Associated Autoimmune Diseases and Disorders

### Message from the Guest Editor

Dear all, The interplay between vaccines and autoimmunity is well known. Patients with autoimmune rheumatic diseases are of great concern regarding COVID-19 infection and vaccination. SLE patients have a higher risk for COVID-19-related complications, including mortality, compared to age and sex-adjusted controls and other autoimmune rheumatic disease conditions. On the other hand, the risk of autoimmune rheumatic disease flares following the COVID-19 vaccine has raised some concerns. However, overall COVID-19 vaccine appears to be safe among SLE patients, with a low rate of severe adverse effects. In addition, a new onset of autoimmune rheumatic diseases among previously healthy patients vaccinated against COVID-19 has recently emerged sporadically. To improve the understanding of the relationship between vaccines and new diagnoses of autoimmune diseases, this special issue of *Vaccines* focuses on researching this phenomenon. We encourage researchers to contribute original studies, reports, and reviews of the epidemiology, molecular pathways, and clinical and management of newly onset autoimmune conditions related to vaccine uptake.

### Guest Editor

Dr. Iftach Sagy

Rheumatic Diseases Unit, Soroka University Medical Center, Beer Sheva, Israel

### Deadline for manuscript submissions

closed (30 November 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/178851](https://mdpi.com/si/178851)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).